Understanding the clinical pharmacology of antiretroviral therapy is pivotal to designing optimal treatment and prevention strategies for HIV & Hepatitis infection. Drug exposure is significantly influenced by drug interactions, medication taking behavior, and patients’ physiologic and genetic characteristics. These factors are central to determining therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacologic challenges still exist.
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy will provide a platform for state-of-the-art discussions of current topics fundamental to the optimal use of antiretroviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance project, and regulatory considerations.
The Clinical Pharmacology workshop is a unique platform where industry pharmacologist and academic pharmacologists sharing and discussing the latest developments in clinical pharmacology. Improved knowledge on drug efficacy/toxicity and potential drug interactions enables clinicians to further optimize antiviral treatment for their HIV and/or Hepatitis infected patients.
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy will be held 8 - 10 June 2016 in Washington DC, USA.